ATOS
ATOSSA THERAPEUTICS, INC.
Key Financials
Gross Profit
$-130653
0.0%
Net Income
$-34770000
↓ 36.3%
Revenue
$1758
0.0%
EPS (Diluted)
$-4.04
↓ 1920.0%
Operating Income
$-37141000
↓ 34.5%
Total Liabilities
$8.3M
↑ 66.2%
Total Assets
$47.6M
↓ 37.7%
Shareholders' Equity
$39.4M
↓ 44.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 5/14/2026 | View on SEC |
| 4 | 5/14/2026 | View on SEC |
| 4 | 5/14/2026 | View on SEC |
| 4 | 5/14/2026 | View on SEC |
| 4 | 5/14/2026 | View on SEC |
| 4 | 5/14/2026 | View on SEC |
| 8-K | 5/8/2026 | View on SEC |
| 10-Q | 5/8/2026 | View on SEC |
| 8-K | 5/8/2026 | View on SEC |
| 8-K | 4/16/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ATOS |
| Company Name | ATOSSA THERAPEUTICS, INC. |
| CIK | 1488039 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 206.588.0256 |